CJC-1295 vs MK-677 (Ibutamoren): Cost and Access Head-to-Head

How These Two Peptides Raise Growth Hormone

CJC-1295 and MK-677 both increase circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1), but they do so through completely different receptor pathways. This distinction drives nearly every difference in cost, access, dosing logistics, and side-effect profile between the two compounds.

CJC-1295: A GHRH Analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with 30 amino acids. The modified GRF (1-29) version, sometimes called "mod GRF" or "CJC-1295 without DAC," has a half-life of roughly 30 minutes and is typically injected 1-3 times daily 1. A drug-affinity-complex (DAC) variant binds to albumin and extends the half-life to 6-8 days, allowing less frequent dosing. Teichman et al. Demonstrated that a single subcutaneous dose of CJC-1295 with DAC sustained GH and IGF-1 elevation for up to 8 days in healthy adults (N=33), with dose-dependent IGF-1 increases of 1.5- to 3-fold above baseline 1.

MK-677: A Ghrelin Receptor Agonist

MK-677 (ibutamoren) mimics ghrelin at the GHS-R1a receptor. Unlike CJC-1295, it is a non-peptide compound taken orally 2. Murphy et al. Showed that MK-677 at 25 mg daily produced sustained 24-hour GH pulsatility and raised IGF-1 by approximately 40% over baseline across two months of dosing, without tachyphylaxis 2. A separate 2-year randomized controlled trial by Nass et al. (N=65 healthy older adults) confirmed that 25 mg daily MK-677 restored IGF-1 to young-adult reference ranges while maintaining the normal pulsatile pattern of GH secretion 3.

The practical difference is significant. CJC-1295 pulses GH through the hypothalamic GHRH pathway and retains negative-feedback sensitivity, while MK-677 acts on the ghrelin axis and can override some feedback cues, which contributes to its effects on appetite and glucose metabolism 4.

Cost Breakdown: What Each Peptide Actually Costs

Neither CJC-1295 nor MK-677 is manufactured by a major pharmaceutical company, so pricing depends entirely on compounding pharmacies, peptide suppliers, and telehealth clinic markup. No standardized retail price exists for either compound.

CJC-1295 Pricing

A 30-day supply of CJC-1295 (modified GRF 1-29) from a licensed US compounding pharmacy ranges from $150 to $350, depending on dose, concentration, and whether it is combined with ipamorelin in a single vial. Combination vials (CJC/ipamorelin blends) typically run $180-$300 per month. Supplies for injection (syringes, alcohol swabs, bacteriostatic water) add $10-$25 monthly. Telehealth platform fees for the prescriber consultation range from $99 to $250 for the initial visit, with follow-ups costing $50-$150 5.

MK-677 Pricing

MK-677 costs $50-$150 per month at 25 mg daily from research chemical suppliers and some compounding pharmacies. Because it is orally bioavailable and non-peptide, it does not require cold-chain shipping or reconstitution, which reduces logistics costs. Some compounding pharmacies charge $100-$200 for a 30-day supply of pharmaceutical-grade ibutamoren capsules. Research-grade liquid MK-677 from online vendors can cost as little as $40-$60 per month, though quality verification is limited 6.

Total Annual Cost Comparison

Over 12 months, CJC-1295 therapy typically costs $2,100-$4,800 (peptide plus supplies plus clinic visits). MK-677 costs $600-$2,400 annually, depending on source. The price gap narrows when both are obtained through the same compounding pharmacy, but MK-677 remains 40-60% less expensive on a per-month basis for most patients.

Insurance and Coverage: Both Are Out-of-Pocket

No commercial health insurer, Medicare plan, or state Medicaid program covers CJC-1295 or MK-677 for any indication. This is because neither has received FDA approval, and both lack a National Drug Code (NDC) in the standard formulary databases 5.

Why Insurance Won't Cover Either

FDA approval is the threshold requirement for formulary inclusion. The FDA has not approved CJC-1295 or MK-677 for GH deficiency, anti-aging, body composition, or any other indication 7). Compounded peptides fall under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which permits compounding for individual prescriptions but does not create an insurance-reimbursable pathway 5. Health Savings Account (HSA) or Flexible Spending Account (FSA) funds may cover compounded prescriptions if a licensed provider writes the prescription, though this varies by plan administrator.

Prior Authorization and Appeals

Because no FDA-approved product exists for either compound, prior authorization requests will be denied. There is no appeals pathway that applies. Patients prescribed FDA-approved recombinant GH (somatropin) for documented GH deficiency can sometimes obtain coverage through prior authorization, but the Endocrine Society's 2011 clinical practice guideline for adult GH deficiency specifies stimulation testing criteria that most peptide-therapy candidates do not meet 8.

Access Channels: Where and How Patients Get Each Compound

Compounding Pharmacies for CJC-1295

CJC-1295 is available through 503A and 503B compounding pharmacies in the United States. The FDA's bulk drug substance list determines which compounds pharmacies may legally compound 5. A valid prescription from a licensed provider is required. Telehealth platforms specializing in peptide therapy have expanded access significantly since 2020, with several offering nationwide virtual consultations and direct pharmacy shipping.

Gray-Market Access for MK-677

MK-677 occupies a regulatory gray area. It is not a controlled substance, not FDA-approved, and not classified as an anabolic steroid under the Anabolic Steroid Control Act. It is sold by research chemical companies labeled "for research purposes only" or "not for human consumption." The FDA has issued warning letters to companies selling SARMs and GH secretagogues with therapeutic claims 6. The World Anti-Doping Agency (WADA) lists ibutamoren as a prohibited substance under section S2 (peptide hormones, growth factors, and related substances) 9.

Some US compounding pharmacies do compound MK-677 capsules under a prescription, which provides pharmaceutical-grade purity and dosing accuracy. This route costs more than research suppliers but reduces the risk of contamination or mislabeling.

State-Level Variation

Compounding pharmacy regulations vary by state. Florida, Texas, and California have large numbers of 503B outsourcing facilities that ship peptides nationwide. States with restrictive compounding laws may limit in-state access but cannot block shipments from out-of-state 503B facilities operating under federal oversight 5.

Efficacy and Value: What You Get for the Money

GH and IGF-1 Elevation

Both compounds raise GH and IGF-1. Teichman et al. Reported that CJC-1295 with DAC produced IGF-1 increases of 1.5- to 3-fold at doses of 30-60 mcg/kg in single-dose studies 1. Murphy et al. Showed MK-677 at 25 mg daily raised mean 24-hour GH concentration by 97% and IGF-1 by approximately 40% after 2 weeks of dosing 2. Direct comparison is impossible because no head-to-head trial exists, but the magnitude of IGF-1 elevation appears broadly similar at commonly used doses.

Body Composition Data

A 12-month RCT of MK-677 in older adults (N=292) by Bach et al. Found no significant increase in fat-free mass or strength compared to placebo, despite sustained IGF-1 elevation 4. Nass et al. Reported a 1.1 kg increase in fat-free mass with MK-677 over 1 year in a smaller cohort, which was statistically significant but clinically modest 3. Published body composition data for CJC-1295 in humans is limited to short-duration pharmacokinetic studies; no long-term RCT has measured lean mass or fat mass outcomes with CJC-1295 in any formulation 1.

Cost-per-Outcome Perspective

Given the limited evidence for clinically meaningful body composition changes with either compound, the cost-per-outcome calculation is difficult to justify on published data alone. MK-677 has more human trial data supporting sustained GH/IGF-1 elevation 10, but the largest RCTs failed to show functional benefits in older adults. CJC-1295 has strong pharmacokinetic data but minimal efficacy-outcome evidence. Patients should weigh these limitations against the out-of-pocket cost before committing to either therapy.

Safety Considerations That Affect Access Decisions

MK-677 and Glucose Metabolism

MK-677 consistently raises fasting glucose and fasting insulin. Nass et al. Reported a mean fasting glucose increase from 5.2 to 5.7 mmol/L after 12 months, with 6 of 32 MK-677-treated subjects meeting criteria for impaired fasting glucose 3. Longer-term data from the Bach et al. 12-month trial confirmed higher HbA1c in the MK-677 group versus placebo 4. The Endocrine Society recognizes that GH and ghrelin-pathway activation can worsen insulin sensitivity, making MK-677 a poor choice for patients with prediabetes or type 2 diabetes 8.

CJC-1295 Safety Profile

CJC-1295 side effects in published trials include injection-site reactions (erythema, induration), transient flushing, and headache 1. The DAC variant produced more prolonged side effects due to its extended half-life. Reports of a death during a clinical trial of CJC-1295 with DAC in 2006 prompted concern, though a direct causal link was not established in published literature. The modified GRF (no-DAC) version has a shorter duration of action and fewer sustained adverse effects in clinical reports.

Monitoring Costs

Both compounds require periodic lab monitoring. Baseline and follow-up labs should include IGF-1, fasting glucose, fasting insulin, and HbA1c at minimum 8. For MK-677, glucose monitoring is especially important given its established effect on insulin resistance 3. Lab panels cost $50-$200 per draw without insurance, adding $200-$800 annually to the total cost of therapy. Some telehealth peptide clinics bundle lab work into their subscription pricing.

Practical Decision Framework: CJC-1295 or MK-677

Choose CJC-1295 When

The patient prefers a compound with GHRH-pathway specificity, already uses injectable peptides (and owns supplies), wants to combine with ipamorelin for synergistic pulsatile GH release, and has access to a prescriber and compounding pharmacy. The higher cost buys a clearer pharmacologic mechanism and potentially better glucose tolerance.

Choose MK-677 When

The patient strongly prefers oral dosing, cost is the primary constraint, and the patient has normal fasting glucose and insulin sensitivity. The oral route eliminates injection barriers and reduces supply costs.

Neither Compound Is Appropriate When

The patient has impaired fasting glucose, type 2 diabetes, or active malignancy. Exogenous GH stimulation is contraindicated in patients with active neoplasia per FDA labeling of all approved somatropin products 7. Patients seeking insurance-covered GH therapy should pursue formal GH stimulation testing and FDA-approved somatropin under endocrinology guidance 8.

Regulatory Outlook and Future Access

The FDA's evolving stance on compounded peptides may affect CJC-1295 access. In 2023, the FDA proposed removing several peptides from the compounding bulk substance list, though CJC-1295 was not among those initially nominated for removal 5. MK-677 faces a different regulatory trajectory: Merck (the original developer) discontinued clinical development after Phase II trials failed to show strong functional outcomes in elderly sarcopenia populations 4. Without a sponsor pursuing FDA approval, MK-677 will remain an off-label, out-of-pocket therapy indefinitely.

Patients using either compound should confirm their source pharmacy holds a valid state license and, for 503B facilities, current FDA registration. Certificates of analysis (COA) verifying identity, potency, and sterility should be available on request for any compounded peptide product 5.